Valuation: Eton Pharmaceuticals, Inc.

Market Cap 1.95B 1.75B 1.61B 1.46B 2.77B 183B 2.84B 19.28B 7.68B 97.85B 7.31B 7.16B 309B P/E 2026 *
33x
P/E 2027 * 25.2x
Enterprise Value 1.95B 1.75B 1.61B 1.46B 2.77B 183B 2.84B 19.28B 7.68B 97.85B 7.31B 7.16B 309B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 6.79x
Free-Float
95.11%
Yield 2026 *
-
Yield 2027 * -
1 day+4.96%
1 week+32.56%
Current month+29.44%
1 month+22.33%
3 months+54.66%
6 months+127.79%
Current year+299.41%
1 week 47.03
Extreme 47.03
68.38
1 month 47.03
Extreme 47.03
68.38
Current year 14.27
Extreme 14.27
68.38
1 year 14.27
Extreme 14.27
68.38
3 years 3.03
Extreme 3.03
68.38
5 years 1.95
Extreme 1.95
68.38
10 years 1.95
Extreme 1.95
68.38
Manager TitleAgeSince
Chief Executive Officer 54 2017-05-31
Director of Finance/CFO 56 2026-05-31
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 54 2017-05-31
Director/Board Member 79 2017-05-31
Chairman 68 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Sell

Executive/Senior Manager

-4,166 0.0146%
8/28/26 Exercice

Director

150,000 0.5476%
8/28/26 Exercice

Director

175,000 0.6122%
Change 5-day change 1-year change 3-year change Capi.($)
+4.96%+32.56%+299.17%+1,658.85% 1.95B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
-0.83%+0.58%+37.93%+66.79% 388B
-0.48%+2.34%+70.66%+46.02% 365B
-0.91%-0.80%+27.96%+57.39% 307B
-0.13%-1.06%+3.04%+35.40% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average +0.29%+5.36%+65.87%+240.59% 428B
Weighted average by Cap. -0.33%+2.52%+42.83%+97.22%

Financials

2026 *2027 *
Net sales 180M 161M 149M 135M 256M 16.87B 263M 1.78B 709M 9.04B 675M 661M 28.57B 287M 257M 237M 215M 408M 26.9B 419M 2.84B 1.13B 14.41B 1.08B 1.05B 45.56B
Net income 65.85M 59.05M 54.42M 49.43M 93.54M 6.17B 96.15M 652M 260M 3.31B 247M 242M 10.46B 96.72M 86.74M 79.94M 72.6M 137M 9.07B 141M 957M 381M 4.86B 363M 355M 15.36B
Net Debt - -
Projected Income Statement - Annual - Eton Pharmaceuticals, Inc.
Logo Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has over 11 commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjectors. INCRELEX (mecasermin) is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. NITISINONE is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). The Company also has licensed United States rights to a rare disease product candidate ASN-001 (timolol topical gel).
Employees
44
Date Price Change Volume
26-11-10 US$67.54 +4.96% 1,176,170
26-11-09 US$64.35 +13.97% 1,139,253
26-11-06 US$56.46 +19.75% 1,270,822
26-11-05 US$47.15 -7.04% 706,180
26-11-04 US$50.72 -0.45% 375,316
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Eton Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
67.54USD
Average target price
78.00USD
Spread / Average Target
+15.49%
  1. Stock Market
  2. Stocks
  3. ETON Stock